/PRNewswire/ Synthetica Bio, a privately held healthcare technology company developing an enterprise-grade, generative artificial intelligence (GenAI).
/PRNewswire/ The "AI-based Clinical Trial Solutions For Patient Matching Market Share, Size, Trends, Industry Analysis Report, By Therapeutic Application;.
Paradigm, a new startup co-incubated by ARCH Venture Partners and General Catalyst, recently launched with $203 million in Series A funding. The company is focused on improving equitable access to trials by creating a less fragmented and more efficient clinical research ecosystem.